BioSpace News Archive

Sosei Group Corporation (“the Company”; TSE: 4565), has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China.

CymaBay Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”) today announced pipeline updates including its continued focus on its hepatitis B virus (HBV) assets, imdusiran (AB-729) as a cornerstone therapy in a functional cure treatment regimen for patients with chronic hepatitis B virus (cHBV), as well as its oral PD-L1 inhibitor, AB-101.

Amphastar Pharmaceuticals, Inc. announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Immunocore Holdings Plc announced that management will present at the following investor conferences in September:

Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis») today announced that it has received FDA (Food and Drug Administration) authorization to launch its SARA-31 study in the US, the first ever phase 3 study in sarcopenia.

Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible) announces the results of the international Phase II/III REVERSE-IT study, demonstrating TOTUM•63’s impressive efficacy on key markers of glucose metabolism, with efficacy results comparable to those of some leading anti-diabetic drugs, in a similar population.

Genesis MedTech, a leading medical device company, today announced that its absorbable sutures with antibacterial protection have successfully obtained approval from the China’s National Medical Products Administration (NMPA) for market release.

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197) today announced the launch of AdimFlu-S (QIS) in mainland China, where it is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older.